Quick Answer
GYRE THERAPEUTICS, INC. reported Net Income Loss of $9.88 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed a decrease of -44.8% in Net Income Loss from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), GYRE THERAPEUTICS, INC.'s Net Income Loss has grown by 125.1%.
- Historical annual values: Fiscal year 2025: $9.88 million | Fiscal year 2024: $17.90 million | Fiscal year 2023: -$85.48 million | Fiscal year 2022: $4.31 million | Fiscal year 2021: -$87.93 million | Fiscal year 2020: -$56.24 million | Fiscal year 2019: -$55.18 million | Fiscal year 2018: -$30.06 million | Fiscal year 2017: -$21.56 million | Fiscal year 2016: -$16.95 million | Fiscal year 2015: -$14.76 million | Fiscal year 2014: -$6.61 million | Fiscal year 2013: -$9.97 million | Fiscal year 2012: -$7.00 million | Fiscal year 2011: -$8.53 million | Fiscal year 2010: $10.90 million | Fiscal year 2009: -$39.40 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: